RCT for ivermectin+doxycycline showing improvements in mortality, recovery, progression, and virological cure. There is no paper yet, results are reported on clinicaltrials.gov. 183 treatment and 183 control patients with no deaths in the treatment arm vs. 3 in the control arm (the 3 control deaths are not included in the analysis of other outcomes). Treatment delay is not specified.
Mahmud et al., 10/9/2020, Double Blind Randomized Controlled Trial, Bangladesh, South Asia, preprint, 1 author, dosage 12mg single dose, this trial uses multiple treatments in the treatment arm (combined with doxycycline) - results of individual treatments may vary.
risk of death, 85.7% lower, RR 0.14, p = 0.25, treatment 0 of 183 (0.0%), control 3 of 183 (1.6%), continuity correction due to zero event (with reciprocal of the contrasting arm).
risk of no recovery, 49.0% lower, RR 0.51, p < 0.004, treatment 42 of 183 (23.0%), control 67 of 180 (37.2%), adjusted per study.
risk of disease progression, 55.0% lower, RR 0.45, p < 0.01, treatment 16 of 183 (8.7%), control 32 of 180 (17.8%), adjusted per study.
risk of no virological cure, 42.0% lower, RR 0.58, p < 0.001, treatment 14 of 183 (7.7%), control 36 of 180 (20.0%), adjusted per study.
Effect extraction follows pre-specified rules
prioritizing more serious outcomes. For an individual study the most serious
outcome may have a smaller number of events and lower statistical signficance,
however this provides the strongest evidence for the most serious outcomes
when combining the results of many trials.